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ABSTRACT
LIMD1 (LIM domain-containing protein 1) is considered as a tumor suppressor,
being deregulated in many cancers to include hematological malignancies; however,
very little is known about the underlying mechanisms of its deregulation and its roles
in carcinogenesis. Epstein-Barr Virus (EBV) is associated with a panel of malignancies
of lymphocytic and epithelial origin. Using high throughput expression profiling, we
have previously identified LIMD1 as a common marker associated with the oncogenic
transcription factor IRF4 in EBV-related lymphomas and other hematological
malignancies. In this study, we have identified potential conserved IRF4- and NFκBbinding motifs in the LIMD1 gene promoter, and both are demonstrated functional by
promoter-reporter assays. We further show that LIMD1 is partially upregulated by EBV
latent membrane protein 1 (LMP1) via IRF4 and NFκB in EBV latency. As to its role in
the setting of EBV latent infection, we show that LIMD1 interacts with TRAF6, a crucial
mediator of LMP1 signal transduction. Importantly, LIMD1 depletion impairs LMP1
signaling and functions, potentiates ionomycin-induced DNA damage and apoptosis,
and inhibits p62-mediated selective autophagy. Taken together, these results show
that LIMD1 is upregulated in EBV latency and plays an oncogenic role rather than that
of a tumor suppressor. Our findings have identified LIMD1 as a novel player in EBV
latency and oncogenesis, and open a novel research avenue, in which LIMD1 and p62
play crucial roles in linking DNA damage response (DDR), apoptosis, and autophagy
and their potential interplay during viral oncogenesis.

INTRODUCTION

is a pleiotropic factor that promotes cell growth and
transformation in vitro as well as in transgenic mice [2].
LMP1 oncogenicity is attributed by its ability to activate
multiple oncogenic transcription factors, including NFκB
that interacts with other EBV oncoproteins to form viral
super-enhancers to regulate expression of a large scale
of host genes involved in lymphoblastoid B-cell growth
and survival [3].

Epstein-Barr Virus (EBV) infection is associated
with more than 50% of AIDS-related lymphomas
(ARLs) and other malignancies such as nasopharyngeal
carcinoma, up to 400 thousand cases each year as
estimated by the World Health Organization (WHO)
[1]. The EBV Latent membrane protein 1 (LMP1)
www.impactjournals.com/oncotarget
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The LIM domain-containing protein 1 (LIMD1) is
a member of the ZYXIN family [4]. Like the oncogenic
transcription factor interferon regulatory factor 4 (IRF4),
overexpression of LIMD1 is a hallmark of ABC subtype
of diffuse large B cell lymphoma (DLBCL) [5]. LIMD1 is
involved in the assembly of numerous protein complexes
by acting as an adaptor protein that interacts with various
proteins such as Rb [6], TRAF6 [7], p62/SQSTM1 [8],
VHL and PHD [9, 10], and LATS and WW45 [11],
and participates in myriad cellular processes including
cell fate determination, cytoskeletal organization,
osteoclastogenesis [8], repression of gene transcription,
cell-cell adhesion, cell differentiation, proliferation and
migration. Interaction of LIMD1 with TRAF6 enhances
the ability of TRAF6 to activate AP1 and negatively
regulates the canonical Wnt receptor signaling pathway
in osteoblasts [7], and interaction with p65 negatively
regulates NFκB activity in human non-small cell lung
cancer cells [12]. Our previous study has shown that
LIMD1 and IRF4 expression levels positively correlate
in different hematological malignancies, including EBVassociated lymphomas [13]. However, the mechanisms
underlying its regulation and its role in the setting of EBV
infection remain uninvestigated.
DNA damage is directly linked to a large range of
human diseases, including aging and cancer [14–16], and
usually has severe effects on the cell—triggering cell-cycle
arrest, cell death or tumorigenesis. Reactive oxygen species
(ROS), which can be produced by diverse conditions of
stress such as chronic viral infection and cancer hypoxia
[17, 18], are one of the major causes of DNA damage
[19]. Most cancers, if not all, harbor deficient DNA repair
mechanisms, resulting in increased genomic instability
and less capacity to respond to DNA damages; therefore
they heavily rely on alternative DNA repair mechanisms
for survival [14]. Deficiency in DNA repair mechanisms
also results in resistance to conventional chemotherapeutic
agents in cancer cells [20, 21], in which DNA damageinduced autophagy plays a cryoprotective role [22, 23].
An increasing body of evidence indicates that
autophagy and DNA damage closely crosstalk, in which
the selective autophagy adaptor p62 (known as SQSTM1/
Sequestosome-1) plays a key role [24–27]. As a part of
the DNA damage response (DDR), autophagy promotes
DNA damage repair by targeting DDR-related proteins
including p62 for degradation, contributing to the
maintenance of genomic stability in aging and cancer [22,
27]. Many cancer cells have high apoptotic thresholds,
so autophagy serves as a survival mechanism that allows
these cancer cells to escape apoptotic or necrotic death
in response to metabolic crisis. Thus, the heavy reliance
of many cancer cells on autophagy for survival suggests
inhibiting autophagy in these cells may be a promising
therapeutic target [23].

www.impactjournals.com/oncotarget

In this study, we show evidence that LIMD1 is
upregulated by LMP1 via NFκB and IRF4 axes in EBV
latency. We further show that LIMD1 is required for
LMP1 signal transduction and function. More importantly,
LIMD1 depletion potentiates ionomycin-induced DNA
damage, and impairs p62-mediated selective autophagy.

RESULTS
IRF4, NFκB, and LMP1 transactivate the
LIMD1 gene promoter
We have previously shown that LIMD1 expression
correlates with IRF4 in hematological malignancies [13],
suggesting that LIMD1 may be transcriptionally regulated
by IRF4. One of the IRF4 consensus binding site is ETS/
ISRE-consensus element (EICE), which has the consensus
sequence 5-GGAANNGAAA-3 fusing the ETS-binding
motif (5-GGAA-3) with the IRF4-binding motif
(5-AANNGAAA-3) [28]. To investigate this possibility
that IRF4 regulates LIMD1 transcription, we analyzed its
promoter region, and identified potential EICE and NFκBbinding sites (Figure 1A), in addition to the known Pu.1binding site [29]. Promoter-reporter assay results further
showed that IRF4, NFκB or LMP1 alone can activate the
human LIMD1 promoter, but IRF7 had no significant
effect on it (Figure 1B). To confirm the two potential sites
are functional, we created a panel of point mutants in these
sites that were then subjected to promoter-reporter assays
(Figure 1A). The results show that mutation of either of
these two sites impairs the LIMD1 promoter activity, and
mutation of both disables LMP1-stimulated promoter
activity (Figure 1C).
We also evaluated the potential cooperation between
IRF4 and Pu.1 in transactivating the LIMD1 promoter, with
the LIMD1 promoter construct mutated in the Pu.1-binding
site [29]. As shown in Figure 1D, cotransfection of IRF4
with Pu.1 results in dramatically increased activity than
IRF4 or Pu.1 alone. EBNA2, an EBV nuclear antigen that
is another Pu.1-binding partner [30], also transactivate the
LIMD1 promoter but not the mutant with Pu.1-binding site
mutated; however, no synergic effect between EBNA2 and
Pu.1 was detected. These data indicate that IRF4 and Pu.1
can transactivate the LIMD1 promoter in a synergic manner.
We further performed ChIP assays to assess the
binding of IRF4 and NFκB with the endogenous LIMD1
promoter in 293 cells. IRF4-DNA and NFκB-DNA
complexes were pulled down with the Flag M2 antibody,
and the recovered DNA fragments were subjected to realtime PCR amplification for a fragment containing the
potential EICE and NFκB-binding sites. Results indicate
that IRF4 and NFκB bind to the LIMD1 promoter in 293
cells (Figure 1E).
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Figure 1: LMP1, NFκB and IRF4 transactivates LIMD1 gene promoter. (A) A diagram showing the LIMD1 promoter

construct pGL4.10/LIMD1p(-1990/+50)-Luc2 and its mutants. (B) LMP1, NFκB and IRF4 transactivate the wild type pGL4.10/LIMD1p(1990/+50)-Luc2. (C) The putative NFκB- and IRF4-binding sites in the LIMD1 promoter are functional. 293 cells in 24-well plates were
transfected with 150 ng IRF4, 150 ng p65 plus p50, or 10 ng LMP1, 40 ng pGL4.10/LIMD1p(-1990/+50)-Luc2 or its mutant with the Pu.1binding site mutated, and 10 ng Renilla. Dual luciferase assay was performed. The ability of the vector control to activate the promoter
construct was set to 1. (D) Pu.1 and IRF4 synergically transactivate the LIMD1 promoter. 293 cells in 24-well plates were transfected with
www.impactjournals.com/oncotarget
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150 ng IRF4, 150 ng EBNA2, 150 ng Pu.1 or their combinations, 40 ng pGL4.10/LIMD1p(-1990/+50)-Luc2 or it mutant with the Pu.1binding site mutated, and 10 ng Renilla. Dual luciferase assays and data processing were performed as above. (E) 293 cells in 100-mm
dishes were transfected with Flag-IRF4, Flag-p65+Flag-p50, or vector control, or mock transfected. Cells were then subjected to
immunoprecipitation with anti-Flag M2 after 48 h, followed by ChIP assays. For each sample, DNA pellets were dissolved in 200 µl ddH2O,
and 15 µl was used for qPCR using the primers for LIMD1 promoter EICE and NFκB-binding site. DNA-binding activity is represented
by relative fluorescence units (RFU). Results are the averages ± standard error (SE) of duplicates. Representative results from at least three
independent experiments are shown.

In conclusion, our results demonstrate that EBV
LMP1 transactivates the LIMD1 promoter via IRF4 and
NFκB signaling axes.

their regulation by NFκB and IRF4 in these cell lines under
normal culture conditions (Figure 2E; Figure 3).
Taken together, our results demonstrate that LIMD1
is upregulated by NFκB and IRF4 downstream of LMP1
signaling pathway.

LIMD1 expression is upregulated by IRF4 and
NFκB downstream of LMP1 signaling

LIMD1 physically interacts with LMP1 and
TRAF6

We next evaluated the regulation of LIMD1
expression by IRF4, NFκB, and LMP1. We have
previously shown that LIMD1 expression is associated
with IRF4 in EBV-positive and negative B lymphoma cell
lines [13]. We further show here that the LIMD1 protein
level is associated with NFκB activity (as indicated by
IκBα phosphorylation), in B and T lymphoma cell lines
(Figure 2A). In EBV-negative B cells and type I latency
where p-IκBα(S32/36) is not detected, LIMD1 levels are
low or undetectable; however, in EBV type III latency and
in MT4 T cell line where p-IκBα(S32/36) is considerable,
LIMD1 expression is readily detectable (Figure 2A).
Notably, in P3HR1 cells derived from the parental
JiJoye cell line but lacking LMP1 expression due to the
deletion of the EBNA2 gene, LIMD1 is also expressed
at a considerable level; it is however consistently lower
than that in the parental cell line JiJoye, indicating that
mechanisms other than LMP1 signaling may contribute to
the induction of LIMD1 expression in EBV latency.
We then assessed LIMD1 expression in several cell
lines including DG75, BJAB and Akata that stably express
LMP1 vs. vector control. The data show that stable
expression of LMP1 elevates LIMD1 protein levels in
these cell lines (Figure 2B). However, transient expression
of high level of LMP1 promotes proteasome-mediated
degradation of LIMD1 (see Figure 4). We then assessed
the LIMD1 protein levels in IB4 cell line stably expressing
IRF4 or scramble control short hairpin RNAs (shRNAs)
that were induced by doxycycline (Dox). The shIRF4
cloned in pTRIPz and control were used in our previous
publication [31]. Results show that IRF4 deficiency results
in a consistent decrease in endogenous LIMD1 protein
levels in IB4 cells (Figure 2C). We have further blocked
endogenous NFκB activity in EBV-positive cell lines with
type III latency and in HTLV1-positive MT4 cell line
using the IKKβ-specific inhibitor Bay11-7085 and then
evaluated LIMD1 protein levels. Results show that NFκB
blockage inhibits LIMD1 expression (Figure 2D).
We also evaluated LIMD1 regulation at the
transcriptional level using real-time quantitative PCR, and the
data indicate that LIMD1 mRNA and protein are consistent in
www.impactjournals.com/oncotarget

The upregulation of LIMD1 by LMP1 signaling
implicates that LIMD1 may play a role in EBV latency
and oncogenesis. As an adaptor protein, LIMD1 interacts
with TRAF6, and is a positive regulator of NFκB and AP1
activation; however, it negatively regulates the canonical
Wnt receptor signaling pathway in osteoclastogenesis
[7, 8]. The closest family member, Ajuba, also positively
regulates IL1-stimulated NFκB activation [32]. Thus, we
first verifed that endogenous LIMD1 and TRAF6 clearly
interact in EBV-transformed cells (Figure 4A). We have
further shown that endogenous LIMD1 interacts with LMP1
as well (Figure 4B). To define the specificity of LIMD1/
LMP1 interaction, we transiently expressed a panel of
3XFlag-LMP1 deletion mutants (Figure 4C, upper panel)
with LIMD1 in 293T cells, and cell lysates were collected
for immunoprecipitation. Our results show that both LMP1
CTAR1 and CTAR2 interact with LIMD1, and deletion of
both ablated its ability to interact with LIMD1 (Figure 4C,
lower panel).
Of note, our results consistently show that
overexpression of the full length of LMP1, LMP1 CTAR1
or CTAR2 results in significantly lower levels of LIMD1
protein (Figure 4C, lower panel). This downregulation
occurred at the post-translational level since it was
prevented by treatment of the cells with MG132, a 26S
proteosome specific inhibitor (Figure 4C, lower panel).
Similar effects of MG132 on endogenous LIMD1 proteins
were observed in EBV+ B cells with high levels of LMP1
(Figure 4D). These observations imply that high levels of
LMP1 promote LIMD1 degradation through a proteosomedependent pathway. We will further investigate these
findings and the underlying mechanism, including
identification of LIMD1 ubiquitination sites responsible for
its stability regulation, in a separate project.
Together, these results demonstrate that LIMD1
interacts with both TRAF6 and LMP1 in EBV latency, and
imply that high levels of LMP1 downregulate LIMD1 at
the post-translational level.
6285
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LIMD1 is required for LMP1 signal transduction
and target gene regulation

After selection of the cells with puromycin and induction
of shRNA expression by Dox, we assessed NFκB and
AP1 activity by immunoblotting for phosphorylation
of IκBα and p38. Results show that depletion of LIMD1
significantly attenuates phosphorylation of both IκBα and
p38 that requires TRAF6, but did not have detectable effects
on PTEN and its phosphorylation at S380 downstream
of LMP1/PI3K. These results indicate that LIMD1 is
specifically required for LMP1/TRAF6-mediated signal
transduction.

Since LIMD1 interacts with TRAF6, a crucial
mediator for LMP1 activation of NFκB and AP1, we next
evaluated the requirement of LIMD1 for LMP1 signal
transduction. To this end, we first depleted endogenous
LIMD1 expression using LIMD1-specific shRNAs.
As shown in Figure 5A, we achieved high knockdown
efficiency using two out of six LIMD1 shRNA constructs.

Figure 2: LIMD1 is upregulated by NFκB and IRF4 in virus-transformed cells. (A) LIMD1 expression is correlated with

NFκB activity in B and T cell lines. (B) LMP1 induces LIMD1 expression. BJAB and Akata stable cell lines expressing LMP1 or control
were generated by transfecting with pLXCN/Flag-LMP1 expression and control plasmids and selected with 2 mg/ml G418 for two weeks,
and then subjected to immunoblotting analysis for LIMD1 protein. LMP1 in DG75 stable cells was induced by 1 µg/ml doxycycline for
48 h before collection. All cells were treated with 5 µM MG132 for 6 h before collection. (C) Knockdown of IRF4 in IB4 cells decreases
LIMD1 protein level in EBV-transformed cells. IB4 stable cell lines expressing pTRIPz/shIRF4 or control were induced with 1 µg/ml
doxycycline, and IRF4 and LIMD1 protein levels were evaluated. (D) Inhibition of NFκB activity decreases LIMD1 protein levels in
virus-transformed cells. NFκB activity was inhibited with the NFκB-specific inhibitor Bay11-7085 at the concentration of 2.5 µM for
48 h. (E) IRF4 depletion by IRF-specific shRNA downregulates LIMD1 mRNA expression in JiJoye cells. JiJoye cells stably expressing
control and IRF4 shRNAs were treated with 1 µg/ml doxycycline to induce shRNA expression for 96 h. Total RNAs were extracted for
qPCR to quantitate IRF4 and LIMD1 mRNA expression. The average mRNA levels of the duplicates in shControl-expressing cells were
set to 100%.
www.impactjournals.com/oncotarget
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Figure 3: LIMD1 mRNA level is associated with EBV latency and upregulated by LMP1. (A) RNA was extracted from

indicated different pair of cell lines, and LIMD1 mRNA expression level was evaluated by real-time qPCR. The average mRNA levels of
the duplicates in SavI, BJAB, P3HR1, and CEM were set to 1. (B) Cell lines with high endogenous NFκB activity were treated with 2.5 µM
Bay11-7085 for 48 h. RNA was then extracted for real-time qPCR analysis for LIMD1 expression. The average LIMD1 mRNA levels
of the duplicates in DMSO-treated cells were set to 100%. The LIMD1 mRNA levels decreased by Bay11-7085 treatment are shown as
percentage of those with corresponding DMSO controls. Statistical analysis was performed on results from three independent experiments.
www.impactjournals.com/oncotarget
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We next assessed the requirement of LIMD1
in regulation of LMP1 target gene expression. We
performed immunoblotting and real-time qPCR for
selected LMP1 targets, including IRF4, IRF7, and Bcl6
[33–35]. Our data show that protein levels of IRF4
and IRF7 are significantly downregulated in LIMD1
shRNA-expressing cells, compared with control

shRNA-expressing cells (Figure 5B), and Bcl6 mRNA
levels are increased (Figure 5C). We also show that
p62 mRNA is downregulated in LIMD1-deficient cells
(Figure 5C).
Taken together, these results indicate that LIMD1 is
required for LMP1 signal transduction and regulation of
its target genes.

Figure 4: LIMD1 interacts with TRAF6 and LMP1 in EBV latency. (A) IB4 and JiJoye cell lysates were subjected to

immunoprecipitation with the TRAF6 antibody clone 1H4L2 and then immunoblotting with the LIMD1 antibody clone H-4 (upper), or
vice versa (bottom). (B) IB4 and JiJoye cell lysates were subjected to immunoprecipitation with the LMP1 antibody clone CS1-4 and
then immunoblotting with the LIMD1 antibody H-4 (upper), or vice versa (bottom). (C) Upper panel: A diagram of the LMP1 deletion
mutants for immunoprecipitation. Lower panel: 3XFlag-LMP1 and its mutants were co-transfected with pcDNA3/LIMD1 into 293T
cells. After 48 h, cells were collected and cell lysates were subjected to immunoprecipitation with the LIMD1 antibody clone H-4, and
immunoprecipitants were probed with the Flag antibody M2. For MG132 treatment, MG132 was added at a final concentration of 10 µM
for 6 h before collection. (D) Cells were treated with MG132 at a final concentration of 10 µM for 6 h before collection. Cell lysates were
subjected for IB with the indicated antibodies.
www.impactjournals.com/oncotarget
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Figure 5: LIMD1 is required for LMP1 signal transduction and regulation of target genes. (A) and (B) IB4 cell lines stably

expressing LIMD1 shRNA #1 and #2 were induced by 1 µg/ml doxycycline for 48 h for LIMD1 shRNA expression, and cell lysates were
then subjected to immunoblotting for analysis of the LMP1 downstream pathway activity and target gene expression. (C) LIMD1, IRF4,
p62 and Bcl6 in IB4 stable cell line expressing LIMD1 shRNA #1 were also analyzed at mRNA levels using real-time quantitative PCR.
The average mRNA levels of the duplicates in shControl-expressing cells were set to 100%.
www.impactjournals.com/oncotarget
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LIMD1 depletion potentiates DNA damageinduced cell death and inhibits autophagy

suppression by dampened LMP1/NFκB signaling
(Figure 6B). Additionally, after LIMD1 depletion, LMP1
protein levels are generally lower even in the absence of
autophagy (Figure 6B). This could be explained by our
above results that LIMD1 depletion blocks LMP1 signal
transduction, and consequently impairs NFκB activity that
is involved in LMP1 autoregulation [44]. We obtained
similar results from JiJoye cells that were derived from a
BL cancer patient, i.e. LIMD1 depletion results in severer
DNA damage, diminished autophagy and increased p62
protein levels (Figure 6C).
In general, autophagy precedes apoptosis, which
occurs when the protective ability of autophagy is
overcome by a stimulus such as ionizing radiation or
chemotherapeutic anticancer agents; in turn, apoptosis
inhibits autophagy [45–47]. The Bcl2 family plays a key
role in linking these two processes [48, 49]. To explore
the mechanism underneath ionomycin induction of p62mediated autophagy and the role of LIMD1 in this process,
we evaluated the expression regulation of selected Bcl2
family members, including Bim, Noxa, BNIP3, and BclxL, which have been documented in autophagy [48, 49].
The protein level of the pro-apoptotic Bim, but not Noxa,
is increased after LIMD1 depletion and futher elevated
by ionomycin treatment (Figure 6D). Bim can inhibit
autophagy by directly interacting with Beclin 1 [50].
Other tested Bcl2 family members did not change at
protein levels after LIMD1 depletion (data not shown).
These results suggest that LIMD1 depletion inhibits p62mediated autophagy through upregulating Bim expression.
Taken together, our results indicate that LIMD1
confers EBV-transformed cells resistance to DNA damage
and apoptosis, but renders them susceptible to autophagy,
at minimum through suppressing Bim expression.

EBV latent infection causes genomic instability
through different mechanisms independently mediated
by EBNA1 and EBNA3C, and LMP1 [36]; among these
LMP1 inhibits DNA repair in epithelial cells through
distinct mechanisms, including its ability to inhibit DNAPK/AMPK signaling [37], to inhibit PI3K/Akt/FOXO3a
signaling [38], and to downregulate expression of ATM.
ATM is a key PI3K-like kinase that phosphorylates
multiple factors, such as CHK2, 53BP1, BRCA1 and
H2AX, for double-stranded DNA repair [39].
To further assess the functional role of LIMD1
in EBV latency, we evaluated DNA damage and cell
death of IB4 cells stably expressing LIMD1 shRNAs
in response to ionomycin treatment. Ionomycin is an
ionophore used in research to raise the intracellular level
of calcium (Ca2+); intracellular levels of calcium influx
are essential for ROS production [40], causing DNA
damage. Our data show that ionomycin treatment induces
apoptosis in EBV-transformed IB4 cells, as shown by
Annexin V expression (Figure 6A) and caspase 3 activity
(Figure 6B), and also strikingly induces DNA damage, as
evidenced by expression of γH2AX, a hallmark of DNA
double-strand breaks (Figure 6B). Notably, depletion
of LIMD1 significantly potentiates ionomycin-induced
apoptosis (Figure 6A and 6B), and remarkably increases
DNA damage induced by ionomycin (Figure 6B). Taken
together, our results demonstrate that LIMD1 depletion
results in an enhancement in ionomycin-induced apoptosis
and DNA damage.
Consistent with a previous report [41], our results
show that ionomycin treatment elevates the protein level of
p62, which is well known as a selective autophagy adaptor,
and consequently, induces autophagy, as shown by the
expression of LC3-II, a hallmark of autophagy (Figure 6B).
LC3β has two forms, the cytoplasolic form LC3-I and
the autophagosome membrane-bound form LC3-II; the
latter is a hallmark of autophagy. However, LC3-II was
not detected in cells with LIMD1 depletion. p62 itself is
a target of and is degraded by selective autophagy [42].
Correspondingly, p62 is increased at the protein levels in
cells with LIMD1 depletion as a consequence of impaired
autophagy (Figure 6B). Our results thus indicate that
LIMD1 depletion results in attenuation of ionomycininduced, p62-mediated selective autophagy.
In contrast to p62, LMP1 protein levels are
remarkably decreased in cells with autophagy, consistent
with a previous report that LMP1 is degraded by
autophagy [43]. Correspondingly, the anti-apoptotic NFκB
activity, which is stimulated by LMP1, is also impaired
by ionomycin, in line with its ability to induce apoptosis
(Figure 6B). The LIMD1 protein level is decreased
as well, suggesting that LIMD1 is also degraded by
autophagy, or this decrease is due to transcriptional
www.impactjournals.com/oncotarget

DISCUSSION
In this study, we provide solid evidence for the
regulation of LIMD1 expression by LMP1 through the
NFκB and IRF4 signaling axes. We further show that
LIMD1 is required for LMP1 signal transduction and
functions. Moreover, our results have identified LIMD1
as a novel player in EBV latency and oncogenesis by
protecting EBV-transformed cells from DNA damage and
apoptosis but rendering them susceptible to autophagy
(Figure 7).
Our results show that, in P3HR1 cells, which lack
EBNA2 and LMP1, LIMD1 protein and mRNA are still
expressed at considerably high levels, implying that
factors other than EBNA2 and LMP1 in EBV latency
contribute to LIMD1 upregulation. In fact, in addition
to EBNA2, EBNA3s are also Pu.1-binding proteins, and
they may induce LIMD1 expression in cooperation with
Pu.1, which transactivates the LIMD1 promoter [29].
It is also notable that, when LMP1 is overexpressed in
EBV-negative B cells, it caused downregulation, in lieu
6290
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Figure 6: LIMD1 depletion potentiates ionomycin-induced DNA damage and apoptosis, and impairs autophagy.

(A) IB4 cell lines stably expressing LIMD1 shRNA #1 and control were treated with ionomycin for 48 h, and apoptosis was analyzed by
flow cytometry for Annexin V binding. The right graph shows an analysis for a representative experiment with duplicate for each sample
(mean ± SE). (B–D) IB4 cell lines (B) and (D) and JiJoye cell lines (C) stably expressing LIMD1 shRNA #1 and control were treated with
ionomycin for 48 h (B) and (D) or time points (C). 2.5 µg/ml and 5.0 µg/ml in (B) and 2.5 mg/ml in (C) and (D). DNA damage, apoptosis,
and autophagy were evaluated by immunoblotting for related hallmarks: the DNA damage hallmark γH2AX, the autophagy hallmark LC3II, and the apoptosis hallmark Caspase 3 activity. Bim and Noxa were also analyzed.
www.impactjournals.com/oncotarget
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of upregulation, of LIMD1 expression (data not shown),
and also downregulation of Bcl2 that is known to be
upregulated by LMP1 in EBV latency. This parodox can
be explained by the fact that LMP1 plays dual roles in cell
fate; high levels of LMP1 induces apoptosis, rather than
cell transformation [51, 52].
It has been reported that EBNA3A and EBNA3C
cooperate with IRF4 transcriptional complex to inhibit
Bim expression, and therefore protect EBV-positive cells
from DNA damage-induced apoptosis [53, 54]. We show
here that LIMD1 depletion results in upregulation of Bim,
consistent with our conclusion that LIMD1 is required

for LMP1 signal transduction in that LMP1 induces and
activates IRF4 [55]. It has also been shown that, however,
ionomycin-induced apoptosis is dependent of neither
p53 nor Bim in EBV-positive cells [56], but depends
on another pro-apoptotic Bcl2 family member Noxa
[53], whose expression was not changed in response to
ionomycin treatment in our experiments. Nevertheless, it
is worthy of further investigation to assess the interaction
between Bim and LIMD1 in EBNA3 inhibition of
apoptosis in response to different chemotheraputic drugs.
LIMD1 depletion is associated with more severe
DNA damage in EBV-transformed cells in response to

Figure 7: A diagram showing the interplay between LIMD1 and LMP1. LMP1 induces LIMD1 expression via NFκB and IRF4

axes. In turn, LIMD1 participates in LMP1 signal transduction by interacting with TRAF6. LIMD1 protects EBV-transformed cells from
DNA damage through inducing p62-mediated autophagy that plays a crucial role in DNA repair in cancers, and this function may or may
not depend on LMP1 signaling in that LIMD1 may be regulated and promotes DNA repair through other LMP1-independent mechanisms.
LMP1 may induce autophagy through distinct but not fully understood mechanisms, one of which involves p62 that is likely induced by
LMP1/NFκB. The pathways with broken lines represent several possible LMP1-dependent and -independent mechanisms underlying EBV
regulation of p62-mediated autophagy, and are under our investigation. ① LIMD1 participates in LMP1 signal transduction to NFκB
activation and ROS production, both of which induce p62; ② Other EBV factors may indirectly induce p62 expression; for example,
EBNA1 and EBNA2 produce ROS that is able to induce p62; ③ LIMD1 inhibits expression of Bim that is known to inhibit p62-mediated
autophagy; ④ p62 interacts with LIMD1 and TRAF6 in a multi-protein complex that facilitates NFκB activation in diverse contexts, and
this mechanism may also function in LMP1 activation of NFκB; ⑤ LIMD1 may regualte p62-mediated autophagy through other LMP1independent strategies.
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ionomycin treatment. This consequence may be attributed
by two mechanisms. The first is that LIMD1 depletion
results in more DNA damage directly. The second is
that LIMD1 depletion impairs a functional DNA repair
machinery. Our results show that, in LIMD1-deficient
cells, p62-mediated selective autophagy in response to
ionomycin treatment is remarkably dampened. Since p62mediated selective autophagy plays a crucial role in DNA
repair in cancer cells [22, 23, 27], we believe that LIMD1
protects EBV-transformed cells from DNA damage by
playing an indispensable role in induction of p62-mediated
selective autophagy, which serves as a survival mechanism
by participating in DNA repair in cancer cells that are
usually deficient in traditional DNA repair mechanisms
such as non-homologous end jointing (NHEJ) [14, 23].
We are now investigating potential LMP1dependent and independent mechanisms underlying the
interplay between p62-mediated autophagy and DDR in
EBV latency. In fact, we show here that LIMD1 depletion
promotes Bim protein expression, and Bim is known to
inhibit autophagy [50]. As a second possible mechanism,
LIMD1 is required for LMP1 signaling, which is known
to regulate unfolded protein responses and autophagy
through multiple mechanisms that have not been fully
disclosed, including its ability to induce autophagy through
its N-terminal six transmembrane domains and its ability
to induce ROS that induces autophagy [17, 43, 57–61].
Third, p62 is known to be upregulated in response to ROS
production that is induced individually by three LMP1
latent proteins, including LMP1, EBNA1, and EBNA2
[36, 57, 62]. Fourth, it is interesting that p62 interacts
with LIMD1 in the multi-protein complex LIMD1-p62TRAF6-PKCζ that regulates IL1 and RANKL signaling
[7, 32]. The association between p62 and TRAF6 also
facilitates NFκB activation in Ras, TNFR, nerve growth
factor (NGF), and Toll-like receptor (TLR) signaling
pathways [63–67]. Considering that LMP1 interacts with
p62 in a high throughput screen [68], it is conceivable that
both LIMD1 and p62 interact with TRAF6 downstream
of LMP1 signaling and cooperate to regulate the interplay
between LMP1-mediated DDR and autophagy.
LIMD1 is deemed a tumor suppressor [6]. It represses
the anti-oncogenic Hippo pathway by antagonizing YAP1
phosphorylation [11, 69], and promotes ubiquitinationmediated HIF1α degradation by interacting with the
tumor suppressor VHL [9, 10]. It is also downregulated,
and inhibits NFκB activity and autophagic cell death, in
human non-small cell lung cancer cells [12]. Surprisingly,
its expression is positively correlated with expression of
the oncogene IRF4 in EBV latency, and it is required for
LMP1 oncogenic functions and its depletion promotes
DNA damage and apoptosis. It is also overexpressed in
and is a hallmark of ABC DLBCL [5]. Further, our results
indicate that LIMD1 is downregulated at transcriptional
and/or post-translational levels, in cells either with LMP1
overexpression that induces cell death or in response
www.impactjournals.com/oncotarget

to ionomycin treatment that induces DNA damage and
apoptosis. Thus, we believe that LIMD1 plays an oncogenic
role in EBV-associated lymphomas and other hematological
malignancies, although further verification in animal models
is required. The paradox roles of LIMD1 may depend on
its post-translational modifications; cell-cycle-dependent
phosphorylation may play a role in its function as a tumor
suppressor [70].
Our intriguing observations open a novel research
avenue in the field of EBV oncogenesis that involves
DDR, apoptosis, and autophagy, and their interplay
mediated by LIMD1 and p62 in EBV oncogenesis, which
have never been reported. We believe that future in-depth
mechanistic studies will provide key innovative insights
into EBV oncogenesis.

MATERIALS AND METHODS
Constructs, antibodies, and reagents
pGL4.10/LIMD1p(-1990/+50)-Luc2 and its mutant
with the Pu.1-binding site mutated were described
previously [29]. 3XFlag-tagged LMP1 and mutants, and
other expression constructs were described in our recent
paper [55]. Deletion and point mutants were generated
by subcloning or site-directed mutation (Stratagene), and
verified by sequencing. LIMD1 cDNA was amplified from
IB4 cell line with the primer pair: forward: 5′-CCGGAA
TTCATGGATAAGTATGACGACCTGG-3′ and reverse:
5′-GCTCTAGACTAGAAGTGGTGCTGGTGAAGG-3′,
and cloned into pcDNA3 at EcoRI and XbaI sites and
verified by sequencing. The set of LIMD1 shRNAs that
includes 6 LIMD1 shRNAs constructed in the lentiviral
vector pTRIPz was purchased from Open Biosystems.
We chose two of them with the highest knockdown
efficiencies for loss-of-function assays.
LMP1 mouse monoclonal antibody (clone CS1-4)
was purchased from Dako. IRF4 mouse monoclonal
antibody (clone MUM1p) and goat polyclonal antibody
(clone M17), LIMD1 mouse monoclonal antibody
(clone H4), and p62 mouse monoclonal antibody (D-3)
were from Santa Cruz for immunoprecipitation and
immunoblotting. LC3b rabbit polyclonal antibody was
from Invitrogen. γH2AX(S139) monoclonal antibody was
from BioLegend. TRAF6 rabbit monoclonal antibody
(clone 1H4L2) and rabbit polyclonal antibody (clone
H274) were from ABfinity and Santa Cruz, respectively.
p-p38(Thr180/Tyr182), p-IκBα (s32/36), p-PTEN(S380),
and Bim (C34C5) antibodies were purchased from Cell
Signaling Technology. Flag (clone M2) antibody was from
Sigma. Goat anti-mouse IgG-HRP, mouse anti-rabbit IgGHRP, and mouse anti-goat IgG-HRP, and all other primary
antibodies were purchased from Santa Cruz. BAY11-7085,
ionomycin calcium salt, and doxycycline (Dox) were
purchased from Sigma.
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three washes, proteins on beads were denatured before
separated by SDS-PAGE. Immunoblotting was carried out
with indicated antibodies and signals were detected with
an enhanced chemiluminescence (ECL) kit following the
manufacturer’s protocol (Amersham Pharmacia Biotech).

293 and 293T are human kidney epithelial cell
lines. SavI, SavIII, P3HR1 and JiJoye are human B cell
lines derived from EBV-positive Burkitt’s lymphoma
patients. P3HR1 was derived from JiJoye but does not
express LMP1 due to lacking the entire EBNA2 ORF in
the viral genome [71]. The LCL line IB4 was derived from
umbilical cord B-lymphocytes latently infected with EBV
in vitro. CEM is a HTLV1-negative, EBV-negative T cell
line derived from acute leukemia, and MT4 is a HTLV1transformed CD4+ T cell line derived from umbilical cord
blood lymphocytes. Epithelial cells are cultured with
DMEM plus 10% FBS and antibiotics, and B and T cells
are cultured with RPMI1640 medium plus 10% FBS and
antibiotics. All cell culture supplies were purchased from
Life Technologies.

Real-time quantitative PCR
Quantitative PCR (qPCR) was performed with
the use of SYBR Green (Applied Biosystems), on a
CFX96TM Real-time PCR Detection System (Bio-Rad
Laboratories, Inc.). All reactions were run in duplicates.
Mean cycle threshold (Ct) values were normalized to
18 s rRNA, yielding a normalized Ct (ΔCt). ΔΔCt value
was calculated by subtracting respective control from the
ΔCt, and expression level was then calculated by 2 raised
to the power of respective –ΔΔCt value. The averages of
2^(–ΔΔCt) in the control samples were set to 1 or 100%.
Results are the average ± standard error (SE) of triplicates
for each sample. Primers for real-time qPCR are as follows:
LIMD1: F: 5′-TGGGGAACCTCTACCATGAC-3′ and
R: 5′-CACAAAACACTTTGCCGTTG-3′; p62: F: 5'-TG
CTAGGCCAGTGAAGGGAG-3' and R: 5'-CTTGTCTG
TTGTGGGTAAAGCAAC-3'; IRF4: F: 5′-CGGGCAA
GCAGGACTACAAC-3′ and R: 5′-CCTTTAAACAGT
GCCCAAGCC-3′; Bcl6: F: 5′-CGCAACTCTGAAGA
GCCACCTGCG-3′ and R: 5′-TTTGTGACGGAAATG
CAGGTTA-3′. 18 s rRNA: F: 5′-GGCCCTGTAATTG
GAATGAGTC-3′ and R: 5′-CCAAGATCCAACTACGA
GCTT-3′.

Transfection
Lentiviral packing, preparation, infection, and
selection of stable cells by puromycin were performed
as detailed in our previous publication [31, 55]. LIMD1
shRNA expression was induced by 1 µg/ml DOX. For
other transfection of B cells, the Nucleofector kit for
human B cells (Lonza) or the Gene Pulser Xcell system
(Bio-Rad) was used. 293 and 293T cells were transfected
with Effectene (Qiagen) or Fugene HD (Promega).

Promoter-reporter assays
293 cells were transfected with expression plasmids
as indicated together with LIMD1p-Luc2 (or its mutants)
and Renilla as internal transfection control. Empty vector
was used to equalize the total amounts of DNA in all
transfections. Cells were collected 24 h after transfection.
Luciferase activity was measured with equal amounts
(10% of total for each sample) of protein lysates with
the use of a Dual Luciferase Assay kit (Promega), on a
multimode microplate reader (Turner Biosystems). Results
are the mean ± standard error (SE) of duplicates for each
sample. At least three consistent results were obtained
from independent experiments and representative results
are shown. The ability of the empty vector controls to
activate the promoter constructs was set to 1.

Apoptosis assay
Apoptosis was assayed using flow cytometry as
detailed in our previous publication [29], for Annex V
binding (BD Biosciences, San Jose, CA). Caspase 3
activity and apoptosis-related proteins including Bim
expression were evaluated by Western blotting.

Chromosome immunoprecipitation (ChIP)
ChIP was performed in 293 cells as described in our
previous publication [55], with the use of ChIP-IT Express
Enzymatic kit (Active Motif). qPCR was performed
with the human LIMD1 promoter EICE primers: 5′- AA
GGCTGCGGCAAGGGGCCG-3′ (forward) and 5′-CACC
AGGCCTGACTCCTTGG-3′ (reverse), and the NFκBbinding site primers: 5′-TGCGCGCAGGCACAACG
AG-3′ (forward) and 5′- CGTGTCACCCATGGCTGG-3′
(reverse).

Immunoprecipitation and immunoblotting
For endogenous protein interaction, 1 × 107 cells
were used for each IP. For interaction between transiently
expressed proteins, 293T cells in 60-mm dishes were
collected 48 h after transfection. Cells were lysed with
NP40 lysis buffer (150 mM NaCl, 1% NP-40, 50 mM
Tris-pH 8.0, plus protease inhibitors), and cell lysates
were subjected to immunoprecipitation with 1.5 µg
indicated antibodies for overnight, and then incubated
with 40 µl Protein A/G beads (Santa Cruz) for 1 h. After
www.impactjournals.com/oncotarget

Statistical analysis
Unpaired, two-tailed student t tests were executed
using Graphpad Prism (version 5) to determine the
differences between two data sets obtained from three
independent experiments. p < 0.05 (*) and p < 0.01
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(**) were considered significant and p < 0.001 (***) was
considered very significant. Data are expressed as mean
± standard error (SE) of duplicate or triplicate samples,
and representative results from at least three with similar
results are shown.
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